A new agency and money for drugs for rare diseases are only very partial steps on the road towards what Canada really needs: a national pharmacare plan.
It takes about three years for safety problems to be identified in new drugs, newer drugs are almost always more expensive, and yet Canadian doctors still hand out hundreds of thousands of samples.
Two community pharmacists suggest a way for improving the palatability of evidence-based universal pharmacare -- for those working in health insurance, pharmacy and the pharmaceutical industry.
The ongoing NAFTA renegotiations could put a Canadian national pharmacare program in jeopardy, and have a particular impact on Canadians who need expensive arthritis drugs. Here's how.
As Canadians consider possibilities for pharmacare reform in the coming months, they should have access to the best available evidence about how it might work in our country.
The cost of a life-saving drug in Canada is rising by 3,000 per cent. A national pharmacare plan could bring order to this chaotic world of Canadian drug prices.
Will Ottawa's new advisory council on pharmacare amount to "just another study," or is a national program truly within reach?
Canada is the only nation with a broad public health system lacking universal coverage for pharmaceuticals. Despite fears that pharmacare would be too costly, it could end up saving Canadians money.